

Formulary Evaluation of Targeted Oncology Therapies: Pharmaceuticals and Therapeutics Workflow Insights from a Pacific Northwest Health System



Amlan Barik | Washington State University

Background

Targeted therapies have facilitated better prognosis for some cancer disease states.

Targeted therapies are requested by clinicians for addition to formularies to fulfill healthcare needs.

Comprehensive new medication review allows for approval for use at healthcare systems level.

Objective(s)

Explain the clinical and operational impact of adding targeted therapies to a health system formulary.

Support evidence-based, system-aligned formulary decisions that enhance delivery and patient outcomes.

Methods

P&T review process of two new anticancer medications were studied.

Pharmacoeconomic considerations were weighted against unfilled healthcare need.

P&T approval and implementation build in EHR was documented.


Discussion

Generalizability to applicable population within health system must be further addressed. Operational impact of implementation must be addressed with workflow and potential medication errors considered. Potential economic constraints with use must be considered.

Results / Conclusion

Comprehensive formulary evaluations empower pharmacists to educate providers, guide appropriate use, and improve patient-centered therapy decisions. These evaluations support evidence-based, system-aligned formulary decisions that enhance delivery and patient outcomes.

Components of a Multi-Faceted Review for Anti-Cancer Medications



Implementation Barriers

Educate clinicians for appropriate use.

Train healthcare professionals on patient education strategies.

Work with purchasers for product availability and manufacturers of patient assistance programs.

Reference(s)

Lauren I. Karel, Dennis R. DeLisle, Ellena A. Anagnostis, Cindy J. Wordell, Implementation of a formulary management process, *American Journal of Health-System Pharmacy*, Volume 74, Issue 16, 15 August 2017, Pages 1245–1252, <https://doi.org/10.2146/ajhp160193>
Lam SW, Siebenaller C, Earl M, et al. Descriptive comparison of hospital formulary decisions with published oncology valuation methods. *Journal of Oncology Pharmacy Practice*. 2019;26(4):891-905. doi:10.1177/1078155219877927

Disclosure

No financial compensation was received in support of this project